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CC BY-NC-ND license (http://creativeBackground: There is increasing epidemiological evidence indicating that many chronic dis-
eases originate during early life, even before birth, through what are termed fetal program-
ming effects. Prenatal glucocorticoid is frequently used clinically to accelerate the
maturation of the lung, but its long-term effects remain unclear.
Methods: We gave pregnant SpragueeDawley rats either intraperitoneal dexamethasone
(0.1 mg/kg body weight) or vehicle at Gestational Days 14e20 and assessed the effects to
pancreas at Postnatal Days 7 and 120.
Results: We found fewer pancreatic b cell fractions (0.31  0.05 % vs. 0.49  0.05 %,
pZ 0.013) and tissues (0.0017  0.0002 % vs. 0.0025  0.0002 %, pZ 0.042) and decreased
secretion of insulin in response to a glucose challenge at Postnatal Day 105 (1.00  0.19 ng/
mL vs. 1.57  0.17 ng/mL at the 15-minute time-point, pZ 0.046) in rats treated prenatally
with dexamethasone. At Postnatal Day 7 in rats treated prenatally with dexamethasone, the
expression of pancreatic duodenal homeobox gene-1 and V-maf avian musculoaponeurotic
fibrosarcoma oncogene homolog A was lower than that in the rats in the Vehicle group
(0.22  0.07 vs. 1.00  0.41 fold, pZ 0.01, 0.20  0.12 vs. 1.00  0.35 fold, pZ 0.01) while
the histone deacetylases activity (54.2  3.7 ng/h/mL vs. 37.6  3.5 ng/h/mL, pZ 0.012)
and 8-hydroxy-2-deoxyguanosine staining (1.34  0.01 vs. 1.00  0.02 fold, p < 0.01) were
higher.oad, Niao Sung, Kaohsiung, 833, Taiwan.
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Secretion of Insulin in Rats, PediatriConclusion: Prenatal dexamethasone exposure affects early postnatal gene expression related
to pancreas development and may exert an effect on b-cell development at 120 postnatal
days.
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open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Diabetes mellitus is the most common endocrine disorder.
It currently affects over 170 million people and will
potentially affect over 365 million in 2030.1 This will be
accompanied by a steep rise in the complications of the
disease, including ischemic heart disease, stroke, neurop-
athy, retinopathy, and nephropathy.1 Type 2 diabetes is
caused by a combination of genetic and environmental
factors that result in decreased insulin function at its sites
of action and a reduced ability of pancreatic b cells to
elevate insulin secretion in response to increased blood
glucose levels.2
There is increasing epidemiological evidence indicating
that some chronic diseases originate early in life, even
before birth, through what are called programming ef-
fects.3 Barker4 and Hales and Barker5 found that low birth
weight was associated with metabolic disorders later in
life, including insulin resistance and glucose intolerance.
Glucocorticoids are frequently used clinically in prenatal
therapy to accelerate the maturation of the lungs; how-
ever, there is debate on long-term effects into adulthood.6
Dalziel et al7 showed that prenatal exposure to betame-
thasone might result in insulin resistance in offspring at age
30 years. The underlying pathophysiological mechanisms of
these effects are largely unclear.
Maternal administration of dexamethasone to sheep
generated offspring that had increased reactive oxygen
species production in the coronary circulation.8 Verhaeghe
et al9 found that antenatal glucocorticoid elicited a rapid
suppression of the glutathione peroxidase-3 antioxidant
defense system in the umbilical vein. This may contribute
to longer-lasting lipid oxidative damage.
Pancreatic and duodenal homeobox factor-1 (PDX-1),
also known as insulin promoter factor 1, is a transcription
factor that is critical for b cell function and development.10
V-maf avian musculoaponeurotic fibrosarcoma oncogene
homolog A (Maf-a) is also a b cell-specific transcription
factor that functions as a potent activator of insulin gene
transcription.11 Neuronal differentiation 1 (Neuro d1) and
paired box gene 6 (PAX-6) are two critical regulators of
pancreatic b cell development.12,13
In this study, we investigated whether rats treated
prenatally with dexamethasone had deficits in pancreatic
development or in glycemic homeostasis. In addition, we
examined whether the expression of PDX-1 and related
genes changed in the pancreas of rats treated prenatally
with dexamethasone and whether epigenetic effects
played a role. We also examined oxidative stress in the
programming of the pancreas of prenatal dexamethasone-
treated rats.en Y-C, et al., Prenatal Dexameth
cs and Neonatology (2016), http:/2. Material and methods
2.1. Animals
Experiments were performed under the Guidelines for An-
imal Experiments of Chang Gung Memorial Hospital and
Chang Gung University. SpragueeDawley (SD) rats were
housed in the animal care facility in Chang Gung Memorial
Hospital in a 12-hour light/dark cycle with lights on at 7AM.
SD female rats were allowed to mate with male rats for 24
hours. One day later, female rats were separated from the
male rats and housed individually in a standard home cage.
After confirmation of pregnancy on the 14th day after
mating, pregnant females were randomly divided into
prenatal steroid exposure and sham control groups.
2.2. Prenatal steroid exposure
Pregnant SD rats in the prenatal steroid exposure group
were given intraperitoneal (IP) dexamethasone (0.1 mg/kg/
d) at Gestational Days (GD) 14e20. The vehicle control
group received normal saline IP at GD 14e20. The day of
birth was designated Postnatal Day 0 (PD 0). Pups were
weaned at PD 21 and had access to standard chow and
water ad libitum. Only the male offspring were used for
this study. The acute effects of prenatal programming were
assessed at PD 7 while long-term programming effects were
assessed at PD 120. Four groups of rats were used as fol-
lows, with eight per group: (1) Vehicle PD 7 group were rats
sacrificed at PD 7 from mothers given normal saline at GD
14e20; (2) DEX PD 7 group consisted of rats sacrificed at PD
7 from mothers given dexamethasone at GD 14e20; (3)
Vehicle PD 120 group consisted of rats sacrificed at PD 120
from mothers given normal saline at GD 14e20; and (4) DEX
PD 120 group consisted of rats sacrificed at PD 120 from
mothers given dexamethasone at GD 14e20.
2.3. IP glucose tolerance test and insulin tolerance
test measurements
IP glucose tolerance test (IPGTT) was conducted with the
Vehicle PD 120 and DEX PD 120 groups. After an 8-hour fast
at PD 105, blood was collected at five time points from the
left or right lateral tail vein: prior to injection and at 15
minutes, 30 minutes, 60 minutes, and 120 minutes after IP
injection of glucose (2 g/kg body weight). Plasma glucose
levels were measured at all time-points by the enzymatic
(hexokinase) method using a glucose assay kit (Optium
Xceed Diabetes Glucometer, Abbott Laboratories, Abbott
Park, IL, USA) immediately. The serum was collected andasone Exposure Programs the Development of the Pancreas and the
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three time points: prior to injection and at 15 minutes and
30 minutes postinjection. Serum insulin levels were
measured using enzyme-linked immunosorbent assay
(Crystal Chem Inc., Downers Grove, IL, USA). Insulin toler-
ance test (ITT) was performed by injecting insulin (1 U/kg
body weight IP) after a 5-hour fast at PD 112 to Vehicle PD
120 and DEX PD 120 group rats. Blood glucose levels were
measured prior to, and at 15 minutes, 30 minutes, 60 mi-
nutes, and 120 minutes after the insulin injection. Plasma
glucose levels were measured as described above. Aspar-
tate transaminase, alanine transaminase, alkaline phos-
phatase, total cholesterol, and triglyceride levels were
measured by an automated method as described
previously.14
2.4. Pancreas immunohistochemistry
The pancreas was cut into two parts. One part was for
immunohistochemical staining and the other part for gene
expression and histone deacetylases (HDAC), histone acet-
ylation transferase (HAT), and DNA methyltransferase
(DNMT) activity analysis. For immunohistochemical stain-
ing, the pancreases were dissected, fixed, cut into 4-mm
thick sections, and transferred to polylysine-coated slides.
Sections were immunostained for insulin, glucagon, PDX-1,
and 8-hydroxy-20-deoxyguanosine (8-OHdG; Santa Cruz
Biotechnology Inc, Santa Cruz, CA, USA). The immunore-
activity was demonstrated using a horseradish peroxidase-
30-diaminobenzidine cell and tissue staining kit (R & D
Systems, Inc., Minneapolis, MN, USA).
The b cell and a cell fractions were measured using a
Zeiss Axioskop 2 plus microscope (Carl Zeiss, Gottingen,
Germany). All the images of each specimen were captured
using a Cool CCD camera (SNAP-Pro c.f. Digital kit; Media
Cybernetics, Silver Spring, MD, USA). Images were analyzed
using Image-Pro Plus image-analysis software (Media Cy-
bernetics). Briefly, the b cell fraction (%) was measured as
the ratio of the insulin-positive cell area to the total tissue
area on the entire section. Three sections taken at 150 mm
intervals through the pancreas were analyzed from eight
rats in the Vehicle PD 120 and DEX PD 120 groups. The b cell
tissue (%) was obtained by multiplying the b cell fraction by
the weight of the pancreas divided by the body weight of
rats. The a cell fraction and tissue were acquired by
measuring glucagon-positive cells in the same way. The
intensity of 8-OHdG in immunohistochemical staining was
measured using an Olympus BX51 microscope with a DP70
camera and a DP2-BSW Soft Imaging System (Olympus Co.,Table 1 Primers used in real-time polymerase chain reaction.
Gene Sense (50e30)
PDX-1 AAAAGACCCGAGCTTCTGAAA
Maf-a GGAGGTCATCCGACTGAAACA
Neuro D1 CTCGCTGTGAGATCCCCATAG
PAX-6 CTCCTCGTACTCCTGCATGCT
18S rRNA GCCGCGGTA ATTCCAGCTCCA
Maf-aZ V-maf avian musculoaponeurotic fibrosarcoma oncogene hom
box gene 6; PDX-1Z pancreatic duodenal homeobox gene-1.
Please cite this article in press as: Chen Y-C, et al., Prenatal Dexametha
Secretion of Insulin in Rats, Pediatrics and Neonatology (2016), http:/Tokyo, Japan). Images were analyzed using Image J’s
image-analysis software (Media Cybernetics).2.5. Pancreas PDX-1, Maf-a, Neuro d1, and PAX-6
mRNA expression
To measure pancreas mRNA expression, RNA was extracted
using TRI Reagent and then treated with DNase I. RNA (2 mg)
was reverse-transcribed with random primers in a total
volume of 40 mL as previously published.15 Control reverse
transcriptase (RT) reactions were performed by omitting the
RT enzyme followed by polymerase chain reaction (PCR)
amplification. Two-step quantitative real-time PCR was
conducted using Quantitect SYBR Green PCR Reagents ac-
cording to the manufacturer’s protocol on a LightCycler
Real-Time PCR System (Roche Diagnostics Ltd., Taipei,
Taiwan). 18S served as the control housekeeping gene. The
primers used are listed in Table 1. All samples were run in
duplicate (2.5 mL of cDNA/well in a 96-well format). For the
relative quantification of gene expression, the comparative
threshold (CT) cycle method was employed. The averaged
CT was subtracted from the corresponding averaged 18S
value for each sample, resulting in
O
CT.
OO
CT was ach-
ieved by subtracting the average control
O
CT value from
the average experimental OCT. The fold increase was
established by calculating 2
OOCT for experimental versus
control samples.2.6. HDAC, HAT, and DNMT activity assay
HDAC, HAT, and DNMT activities were measured using an
EpiQuik HDAC, HAT, and DNMT activity/inhibition assay kit
(ET Epigentek, Farmingdale, NY, USA) according to the
manufacturer’s instructions. For determination of HDAC
activity, 6-mg nuclear extracts from rat pancreas tissue
were added to each well containing stably captured anti-
body substrate. Samples were incubated at 37C for 60
minutes to allow binding to an enzyme substrate. Subse-
quently, the high affinity acetylated histone antibody
(1 mg/mL) was used to recognize undeacetylated sub-
strate. The amount of the undeacetylated substrate was
inversely proportional to enzyme activity. Finally, the
enzymatic activities of HDAC were detected using a
microplate reader at 450 nm following an enzyme-linked
immunosorbent assay-like reaction. The HAT and DNMT
activity were checked by similar methods.Antisense (30e50)
A GATTCTCTAAATTGGTCCCAGGAA
CCGCCAACTTCTCGTATTTCTC
TAATCGTGAAAGATGGCATTAAGC
GGGCTGACTGTTCATGTGTGTT
CCCGCCCGCTCCCAAGATC
olog A; Neuro D1Z neuronal differentiation 1; PAX-6Z paired
sone Exposure Programs the Development of the Pancreas and the
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Results are presented as mean  standard error of the
mean. Data were analyzed by two-tailed unpaired Student t
test. All analyses were performed using the Statistical
Package for the Social Sciences (SPSS) software version 15
(SPSS Inc., Chicago, IL, USA) in a PC-compatible computer.
Significance was defined as p < 0.05 for all tests.
3. Results
The litter size and sex ratio did not differ between the
Vehicle control group and prenatal steroid exposure group
(litter size 12.4  0.9 vs. 10.8  0.6; female/male ratio
1.2  0.1 vs. 1.3  0.2). The birth bodyweight was less in
the prenatal steroid exposure group than the Vehicle con-
trol group (5.92  0.12 g vs. 7.97  0.15 g, pZ 0.001).16
There was no significant difference in pancreas weight or
total body weight between the Vehicle PD 7 and DEX PD 7
groups or between the Vehicle PD 120 and DEX PD 120
groups. There was also no difference in the biochemical
profiles between the Vehicle PD 120 and DEX PD 120 groups.
The mortality rates of the four groups of animals were all
0% (Table 2).
3.1. IPGTT and ITT
There was no difference in the level of plasma glucose at
any of the time points on PD 105 between the Vehicle PD
120 and DEX PD 120 groups (Figure 1A). The serum insulin
level at 15 minutes after IP glucose injection was signifi-
cantly lower in the DEX PD 120 group than in the Vehicle PD
120 group (1.00  0.19 ng/mL vs. 1.57  0.17 ng/mL,
pZ 0.046), but there was no difference in serum insulin
level before glucose injection (0.86  0.12 ng/mL vs.
0.95  0.09 ng/mL, pZ 0.53) or 30 minutes after glucoseTable 2 There was no difference in total body weight or
pancreas weight between the Vehicle and DEX group.
Vehicle DEX p
Group PD7 PD7
Body weight (g) 15.33  0.52 13.6  1.07 NS
Pancreas weight (g) < 0.001 < 0.001 NS
Group PD120 PD120
Body weight (g) 514.05  13.62 540.75  19.77 NS
Pancreas weight (g) 2.44  0.34 3.01  0.2 NS
AST 100  23 100  37 NS
ALT 54  11 43  9 NS
Alkaline
phosphatase
124  24 104  17 NS
Total cholesterol 74  11 74  14 NS
Triglyceride 116  37 120  62 NS
ALTZ alanine transaminase; ASTZ aspartate; DEX PD
7Z prenatal dexamethasone group at Postnatal Day 7; DEX PD
120Z prenatal dexamethasone group at Postnatal Day 120;
GPTZ alanine transaminase; NSZ not significant; Vehicle PD
7Z vehicle group at Postnatal Day 7; Vehicle PD 120Z vehicle
group at Postnatal Day 120.
Figure 1 Intraperitoneal glucose tolerance test and insulin
tolerance test. (A) There was no significant difference of
glucose level at any of the measured points. (B) The serum
insulin level at 15 minutes after intraperitoneal glucose in-
jection was significantly lower in the prenatal dexamethasone
group at Postnatal Day 120 (DEX PD 120) than the vehicle group
at Postnatal Day 120 (Vehicle PD 120). (C) There was no sig-
nificant difference in the level of plasma glucose at any
measured point in the insulin tolerance test.
Please cite this article in press as: Chen Y-C, et al., Prenatal Dexamethasone Exposure Programs the Development of the Pancreas and the
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Figure 2 Immunohistochemistry staining for insulin and glucagon of rat pancreas. There were fewer b cell fractions and b cell
tissues in the prenatal dexamethasone group at Postnatal Day 120 (DEX PD 120) than the vehicle group at Postnatal Day 120 (Vehicle
PD 120) group, but no significant difference in a cell fractions and tissues between these two groups (200). * p < 0.05.
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+ MODELinjection (1.05  0.32 ng/mL vs. 0.92  0.15 ng/mL,
pZ 0.71; Figure 1B). There was no difference in glucose
levels at any time point during the ITT on PD 112 between
the Vehicle PD 120 and DEX PD 120 groups (Figure 1C).3.2. Pancreas immunohistochemistry and gene
expression
There were fewer b cell fractions (0.31  0.05 % vs.
0.49  0.05 %, pZ 0.013) and b cell tissues
(0.0017  0.0002 % vs. 0.0025  0.0002 %, pZ 0.042) in the
DEX PD 120 group than in the Vehicle PD 120 groupPlease cite this article in press as: Chen Y-C, et al., Prenatal Dexametha
Secretion of Insulin in Rats, Pediatrics and Neonatology (2016), http:/(Figure 2). By contrast, there was no difference in the a cell
fractions or tissues between these two groups (Figure 2).
The expressions of PDX-1, Maf-a, Neuro d1, and PAX-6 were
lower in the DEX PD 7 group than in the Vehicle PD 7 group
(PDX-1, 0.22  0.07 vs. 1.0  0.41 fold, pZ 0.01; Maf-a,
0.20  0.12 vs. 1.0  0.35 fold, pZ 0.01; Neuro d1,
0.17  0.03 vs. 1.0  0.29 fold, p < 0.01; PAX-6,
0.17  0.03 vs. 1.0  0.13 fold, p < 0.01; Figure 3A). There
was no difference in the expression of PDX-1, Maf-a, Neuro
d1, or PAX-6 between the DEX PD 120 group and the Vehicle
PD 120 group (Figure 3A). The immunohistochemical stain-
ing for PDX-1 showed fewer stained cells in the islet of
pancreas in the DEX PD 7 group than in the Vehicle PD 7sone Exposure Programs the Development of the Pancreas and the
/dx.doi.org/10.1016/j.pedneo.2016.02.008
Figure 3 Gene expression and immunohistochemistry staining for pancreatic duodenal homeobox (PDX)-1 of rat pancreas. (A)
The expression of PDX-1, -maf avian musculoaponeurotic fibrosarcoma oncogene homolog A (Maf-a), neuronal differentiation 1
(Neuro d1), and paired box gene 6 (PAX-6) were all lower in the prenatal dexamethasone group at Postnatal Day 7 (DEX PD 7) than
the vehicle group at Postnatal Day 7 (Vehicle PD 7), but there was no difference between the prenatal dexamethasone group at
Postnatal Day 120 (DEX PD 120) and the vehicle group at Postnatal Day 120 (Vehicle PD 120). (B) The immunohistochemistry of PDX-1
was consistent with the mRNA expression (200). * p < 0.05.
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the Vehicle PD 120 group, which was in agreement with the
mRNA expression data (Figure 3B). The value of intensity of
8-OHdG in islet in one slide from the Vehicle PD 7 group was
set as 1 and the others’ intensities were decided by the
relative concentrations accordingly. Data presented were
calculated from the sections from six rats in the Vehicle PD
7 and six rats in the DEX PD 7 group. There were higher 8-
OHdG intensities in the DEX PD 7 group than in the
Vehicle PD 7 group (1.34  0.01 vs. 1.00  0.02 fold,
p < 0.01; Figure 4).
3.3. HDAC, HAT, and DNMT activity assay
HDAC activity was greater in the DEX PD 7 group than in the
Vehicle PD 7 group (54.2  3.7 ng/h/mL vs. 37.6  3.5 ng/
h/mL, pZ 0.012), while the HAT and DNMT activity showedPlease cite this article in press as: Chen Y-C, et al., Prenatal Dexameth
Secretion of Insulin in Rats, Pediatrics and Neonatology (2016), http:/no difference between these two groups (Figure 5). There
was no significant difference in HDAC, HAT, and DNMT ac-
tivity between the DEX PD 120 and the Vehicle PD 120 group
(Figure 5).4. Discussion
In this study, we found change in the pancreas following
prenatal dexamethasone exposure including: (1) decreased
b cell mass at PD 120; (2) lower insulin level at the 15-
minute time-point in IPGTT at PD 105; (3) lower PDX-1, Maf-
a, Neuro d1, and PAX-6 expression at PD 7; (4) increased
HDAC activity at PD 7; and (5) more 8-OHdG staining at PD
7.
Decreases in insulin secretion and insulin sensitivity both
occur during the development of Type 2 diabetes. It hasasone Exposure Programs the Development of the Pancreas and the
/dx.doi.org/10.1016/j.pedneo.2016.02.008
Figure 4 Immunohistochemistry for 8-hydroxy-20-deoxy-
guanosine (8-OHdG) staining of rat pancreas. There were
higher 8-OHdG intensities in the islet of pancreas in the pre-
natal dexamethasone group at Postnatal Day 7 (DEX PD 7) than
the vehicle group at Postnatal Day 7 (Vehicle PD 7; 100).
Representative areas are magnified in the lower right corner
(200). Quantification of 8-OHdG is shown in the lower panel.
Data presented were calculated from the sections from six rats
in the Vehicle PD 7 and six rats in the DEX PD 7 group.
* p < 0.05.
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factor in the pathogenesis of Type 2 diabetes. However,
increasing evidence indicating the importance of thePlease cite this article in press as: Chen Y-C, et al., Prenatal Dexametha
Secretion of Insulin in Rats, Pediatrics and Neonatology (2016), http:/pancreatic b cells has accumulated over recent decades.17
Fukushima et al18 reported that Japanese Type 2 diabetic
patients were characterized by a larger decrease in insulin
secretion and less attribution of insulin resistance. Autopsy
studies from various populations showed significant re-
ductions in the pancreatic b cell mass in patients with Type
2 diabetes compared with nondiabetic individuals.17,19
Sakuraba et al20 examined the tail portion of pancreas
from 14 diabetic and 15 nondiabetic patients and found
that total b cell mass was reduced by 30% in diabetic pa-
tients. In our study, decreased b cell mass was found in the
PD 120 group, which means that prenatal dexamethasone
might have a programming effect on pancreas
development.
The second finding in our study was that the DEX PD 120
group had significantly lower serum insulin level at the 15-
minute point in IPGTT but there was no significant dif-
ference at either baseline or 30-minute points compared
with the Vehicle PD 120 group. There was no statistically
significant difference regarding the sugar level at five
time points in either IPGTT or ITT between these two
groups. The current evidence did not support that blood
glucose levels were lower or that insulin sensitivity was
higher in the DEX PD 120 group than in the Vehicle PD 120
group. Alternatively, the blood sugar levels could be
maintained because insulin sensitivity was not diminished
during this period. Further study is necessary to clarify
this point.
Patients with Type 2 diabetes and those with impaired
glucose tolerance exhibit a delayed insulin secretion to a
glucose load.21 However, the progressive b cell dysfunction
may be initiated and rapidly aggravated from the period
generally designated as normal with the defect in the early
phase insulin secretion.22 Decreased early phase insulin
secretion is thought to be an early event in the develop-
ment of Type 2 diabetes,23 and how to restore it has
become a goal in the management of Type 2 diabetes.24 In
rat models of intrauterine growth restriction (IUGR) caused
by bilateral uterine artery ligation, decreased b cell mass
was thought to be one of the causes of blunted early phase
insulin secretion in response to glucose early in life before
the onset of hyperglycemia.25 Kjems et al26 also reported
that decrease in b cell mass might lead to impaired pulsa-
tile insulin secretion in the minipig. Gerich27 stated that
certain individuals were born with genetically abnormal
islets, including reduced islet cell mass, which might limit
the ability to compensate for insulin resistance and raise
the risk to develop Type 2 diabetes. We found that insulin
secretion was less at 15 minutes in the DEX PD 120 than the
Vehicle PD 120 group. The finding that a lower b cell mass is
associated with decreased early phase insulin secretion is
consistent with above reports.
Shen et al28 reported that, in organ cultures, dexa-
methasone could suppress b cell development by down-
regulating PDX-1. Blondeau et al29 found that
glucocorticoid impaired fetal b cell development in rats.
Normalization of corticosterone restored b cell mass in fe-
tuses with undernutrition. Gesina et al30 demonstrated that
glucocorticoid signaling affects pancreatic development in
mice. Dumortier et al31 showed that maternal exposure to
dexamethasone reduced b cell mass in rats, according to
the stages of development. In nonhuman primates, de Vriessone Exposure Programs the Development of the Pancreas and the
/dx.doi.org/10.1016/j.pedneo.2016.02.008
Figure 5 Analysis of histone deacetylases (HDAC), histone acetylation transferase (HAT), and DNA methyltransferase (DNMT)
activity in the rat pancreas. There was greater pancreas HDAC activity in the prenatal dexamethasone group at Postnatal Day 7
(DEX PD 7) than the vehicle group at Postnatal Day 7 (Vehicle PD 7), but there was no difference between the prenatal dexa-
methasone group at Postnatal Day 120 (DEX PD 120) and the vehicle group at Postnatal Day 120 (Vehicle PD 120). * p < 0.05.
8 Y.-C. Chen et al
+ MODELet al32 found that prenatal dexamethasone exposure
induced reduction in b cell mass but did not alter a cell
mass in the offspring. In line with previous reports, we
found that the b cell fraction was smaller and the b cell
tissue was less in the DEX PD 120 than the Vehicle PD 120Figure 6 Hypothetical mechanisms for prenatal glucocorti-
coid exposure that affect the development of the pancreas
and, thereby, the secretion of insulin.
Please cite this article in press as: Chen Y-C, et al., Prenatal Dexameth
Secretion of Insulin in Rats, Pediatrics and Neonatology (2016), http:/group, with no significant difference in the a cell fraction
and tissue.
HDAC activity is important for development of pancreas.
Park et al33 used a rodent model of IUGR and found that
expression of PDX-1 was reduced in b cells and PDX-1 had
received epigenetic modifications throughout develop-
ment, leading to development of diabetes in adulthood.
The fetal IUGR state was characterized by the recruitment
of HDAC 1 and deacetylation of histones H3 and H4 of the
proximal promoter of PDX-1. Furthermore, these epigenetic
changes and the reduction in PDX-1 expression could be
reversed by HDAC inhibition in the neonatal period.33 In
addition, HDAC inhibition may stimulate early events of
pancreatic differentiation in embryonic stem cells.34 The
development of b cell mass of rat pancreas was very rapid
in the perinatal period with the b cell mass increasing 60-
fold and PDX-1 positive cells increasing 20-fold from GD
17 to PD 7.35 After PD 10, the cell proliferation and growth
continued but at a slow rate.36 Compared with the IUGR-
induced progressive influence on PDX-1 expression, we
found the expression of PDX-1, Maf-a, Neuro d1, and PAX-6
to be lower in the pancreas of DEX PD 7 than in the Vehicle
PD 7 group, but no difference existed between the DEX PD
120 and Vehicle PD 120 groups. The decreased expression of
these transcription factors early but not later in life sug-
gests these transcription factors expressions recover after a
period. Even so, lower expression of these transcription
factors early in life may be related to later changes.
The formation of 8-OHdG is a ubiquitous marker of
oxidative stress.37 The finding that there was more 8-OHdG
staining in the pancreas of DEX PD 7 rats than in the Vehicle
PD 7 group suggests that an increased oxidative stress is
induced by prenatal dexamethasone at earlier ages. Bi
et al38 found that prenatal betamethasone exposure pro-
moted an oxidative stress response in the kidney of sheep.
Miller et al39 also showed that maternal betamethasone was
associated with a neuronal integrity disturbance and more
brain cell death due to increased cerebral oxidative stress
in sheep. Therefore, it is reasonable to assume that the
increased oxidative stress during the early development
period affected the development of the pancreas because
the fetal pancreas is more vulnerable to oxidative stress
owing to its reduced antioxidant capacity.40,41asone Exposure Programs the Development of the Pancreas and the
/dx.doi.org/10.1016/j.pedneo.2016.02.008
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group than in the Vehicle PD 7 group; however, there was
no significant difference between the DEX PD 120 and
Vehicle PD 120 groups. Oxidative stress is able to regulate
chromatin remodeling by altering histone acetylation and
deacetylation via HAT/HDAC activity.42 Mihaylova et al43
reported that oxidative stress might increase HDAC activ-
ity and lead to the induction of gluconeogenic genes. Miura
et al44 also stated that hepatitis C virus-induced oxidative
stress suppressed hepcidin expression through increased
histone deacetylase activity. Prenatal ethanol was also able
to increase HDAC activity by inducing oxidative stress.45
Prenatal dexamethasone exposure may increase oxidative
stress, thus affecting the HDAC activity of pancreas in the
early development period.
The hypothesis that oxidative stress may be a connecting
link between intrauterine events and programming conse-
quences after birth is further supported by epidemiological
evidence of oxidant indices associated with Type 2 dia-
betes.46 Hence, we hypothesized that prenatal glucocorti-
coid exposure might generate excessive reactive oxygen
species and decrease the expression of target genes such as
PDX-1 epigenetically, affecting the development of the
pancreas and the secretion of insulin (Figure 6). Gradually,
this would lead to glucose intolerance due to decreased
basal and early-phase insulin secretion. In later life, other
factors, such as diet, may increase the demand on the
pancreatic islets, which they are unable to meet, hence
leading to Type 2 diabetes.47
In conclusion, this study shows potential clinical signifi-
cance because many adult diseases may have started in
childhood or even before birth. A better understanding of
the programming mechanisms is a prerequisite for devel-
oping timely interventions and preventive methods to ar-
rest the increasing epidemic of metabolic syndrome, Type 2
diabetes, and other related disorders.
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